A Comparative Study of Ganglion Cell Complex Thickness Changes in Diabetic Macular Edema and Central Retinal Vein Occlusion Macular Edema: An Optical Coherence Tomography Study

Swapneel Mathurkar 1, Sachin Daigavane 2, Chrisann Saldanha 1

1. Department of Ophthalmology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences University, Wardha, IND 2. Department Of Ophthalmology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences University, Sawangi, Wardha, IND

Corresponding author: Chrisann Saldanha, chrisannsaldanha1609@gmail.com

Abstract

Aim

This study aims to compare the ganglion cell complex changes in diabetic macular edema (DME) and central retinal vein occlusion (CRVO) macular edema using optical coherence tomography (OCT).

Methods

This was a hospital-based cross-sectional study conducted for six months. All patients having DME and CRVO macular edema presenting to the Ophthalmology Department at Acharya Vinobha Bhave Rural Hospital were included in the study. A detailed and comprehensive ophthalmic examination was performed, and OCT was done for each patient.

Results

The incidence of both DME and CRVO macular edema were both found to be maximum in the age group of 61-69 years. DME is more common in males (62.86%) than females (37.14%); the same was observed in CRVO group: 54.29% were males and 45.71% were females. Macular edema showed a mean value of 370.11 in DME and 428.71 in CRVO. Thus, the CRVO group showed more macular edema than the DME group. The ganglion cell complex thickness showed a mean value of 58.47 in DME and 66.77 in the CRVO group, implying that the thickness reduced significantly in the DME group.

Conclusion

OCT provides quantitative measurement of the ganglion cell complex thickness, which helps monitor the course of macular edema secondary to CRVO and diabetes Mellitus and thereby provides an assessment of the prognosis of the disease as these two diseases in particular are major causes of blindness worldwide, and timely care and management can help in altering its course.

Introduction

Diabetes mellitus is an endemic disease and has a rapidly increasing prevalence worldwide [1]. Diabetic retinopathy is an important ocular manifestation of diabetes mellitus. More than 50% of patients with insulin-dependent diabetes mellitus develop retinopathy in around 15 years [1]. In non-insulin-dependent diabetes, the risk of retinopathy increases with the duration of the disease; however, it is generally accompanied by a history of hypertension and smoking [2]. Pathogenesis of this disease consists of micro- and macrovascular complications. The microvascular complications are mainly microaneurysms and retinal microhemorrhages. Macular edema occurs in the majority of eyes and is a significant cause of the diminution of vision in diabetic retinopathy [2].

Central retinal vein occlusion (CRVO) is an ocular pathology that significantly impacts the vision as the retina’s veins get engorged with blood and become tortuous [2]. The retina is filled with many hemorrhages, and many tortuous vessels start to develop around the optic disc. Eventually, in some types of CRVO, the affected retina becomes atrophic with the pigmentary changes. Macular edema is an important consequence of CRVO, which causes significant visual impairment. The main reason is the breakdown of the blood-retinal barrier with the accumulation of fluid in the intra-retinal layer in the macula, causing an increase in vascular endothelial growth factor in the vitreous cavity, thereby increasing macular edema [3].

How to cite this article

Mathurkar S, Daigavane S, Saldanha C (October 23, 2022) A Comparative Study of Ganglion Cell Complex Thickness Changes in Diabetic Macular Edema and Central Retinal Vein Occlusion Macular Edema: An Optical Coherence Tomography Study. Cureus 14(10): e30609. DOI 10.7759/cureus.30609

© Copyright 2022
Mathurkar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Optical coherence tomography (OCT) [4] is an effective diagnostic tool; it helps perform cross-sectional images of biological tissues within less than 10-micron axial resolution using light waves. OCT is a crucial tool in retinal disorders as it allows quantitative measurements of retinal thickness. The ganglion cell complex comprises three layers of the retina, namely the retinal nerve fiber layer, the ganglion cell layer, and the inner plexiform layer [5]. Both diabetic macular edema (DME) and CRVO macular edema have repercussions on the thickness of this layer, thereby making OCT an essential tool as it helps in measuring the thickness of this layer [6,7]. OCT helps quantify the structural changes of different cellular layers of the retina, which thereby helps in identifying potential markers for the disease and monitoring the progression of the disease [8]. Not many studies have been conducted about this in this region.

Objectives

This study aims to compare the ganglion cell complex changes in DME and CRVO macular edema using OCT. We aim to evaluate the thickness of the ganglion cell complex layer in people with DME using OCT and to evaluate the thickness of the ganglion cell complex layer in CRVO patients with macular edema using OCT and to compare the changes between the ganglion cell complex (GCC) layer in DME and CRVO patients with macular edema.

Materials And Methods

This is a hospital-based cross-sectional study conducted at a rural hospital in Central India for six months, from December 2020 to May 2021. All patients having DME and CRVO macular edema were included in the study.

Inclusion criteria

Patients above 18 years of age, patients having insulin and noninsulin-dependent diabetes mellitus with non-proliferative and proliferative diabetic retinopathy with macular edema, and patients having either ischemic or non-ischemic CRVO with macular edema were included in the study.

Exclusion criteria

Patients below 18 years of age, patients with gross retinal pathologies such as degenerative myopia, retinitis pigmentosa, and retinal and choroidal dystrophies and degenerations, or any other retinal disorders affecting the ganglion cell complex and retinal nerve fiber layer, patients with glaucoma or those with intraocular pressure > 21 mmHg in either eye, patients who underwent refractive surgery, patients unable or unwilling to provide informed consent, and patients who have received anti-VEGF treatment for DME- and CRVO-associated macular edema were excluded.

Sampling procedure

A total of 70 patients (70 eyes; 35 DME and 35 CRVO macular edema) who presented to the hospital during the study period were included and distributed on the basis of fundus examination and OCT examination performed by an experienced vitreoretinal surgeon (based on a 95% confidence interval, the prevalence is 0.8% in India and the desired margin of error of 5%=0.05) [9].

Statistical analysis was conducted using descriptive and inferential statistics with the chi-square test. Student’s unpaired t-test and SPSS Version 27.0 (IBM Corp., Armonk, NY) were used in the analysis, and p<0.05 was considered the level of significance.

Results

This study included 70 patients (70 eyes) divided into two groups of 35 each depending on whether they suffered from macular edema due to CRVO or DME. Group 1, included patients having macular edema due to CRVO and group 2 included patients having macular edema due to diabetic retinopathy, both proliferative and non-proliferative.

Table 1 and Figure 1 show the age-wise distribution between the two groups, where maximum patients were found in the age group of 60-69 years in both groups, with a mean age of 63.97 ± 7.62 in the CRVO group (60%) and 66.34 ± 6.05 in the DME group (54.29%).
### TABLE 1: Distribution of patients according to their age in years in two groups

SD, standard deviation; NS, not significant

| Age Group (years) | Diabetic Macular Edema Group | Central Retinal Vein Occlusion Group | Total | \( \chi^2 \) value |
|-------------------|-------------------------------|-------------------------------------|-------|-------------------|
| 40-49             | 0 (0%)                        | 3 (8.57%)                           | 3(4.29%) |
| 50-59             | 4 (11.43%)                    | 2 (5.71%)                           | 6(8.57%) |
| 60-69             | 19 (54.29%)                   | 21 (60%)                            | 40(57.14%)|
| 70-79             | 12 (34.29%)                   | 9 (25.71%)                          | 21(30%)  |
| Total             | 35 (100%)                     | 36 (100%)                           | 70(100%) |
| Mean ± SD         | 66.34 ± 6.05                  | 63.97 ± 7.62                        | 65.15±6.93|
| Range             | 50-76 years                   | 40-75 years                         | 40-76 years |

As shown in Table 2 and Figure 2, the number of males in both groups was more than in females.

### TABLE 2: Distribution of patients according to gender in two groups

NS, not significant

| Gender    | Diabetic Macular Edema Group | Central Retinal Vein Occlusion Group | Total | \( \chi^2 \) value |
|-----------|------------------------------|-------------------------------------|-------|-------------------|
| Male      | 22 (62.86%)                  | 19 (54.29%)                         | 41(58.57%) |
| Female    | 13 (37.14%)                  | 16 (45.71%)                         | 29(41.43%) |
| Total     | 35 (100%)                    | 35 (100%)                           | 70(100%)  |

DME, diabetic macular edema; CRVO, central retinal vein occlusion.
Among both groups, it is shown that in the DME group, macular edema thickness showed a mean of 370.11, and in the CRVO group, macular edema showed a mean of 428.71 (Table 3 and Figure 3). Thus, macular edema thickness in this study was shown to be more in the CRVO group than in the DME group.

| Group                           | Normal | Mean  | Standard Deviation | Standard Error Mean | t-Value | p-Value    |
|---------------------------------|--------|-------|--------------------|---------------------|---------|------------|
| Diabetic macular edema group    | 35     | 370.11| 81.45              | 13.76               | 2.36; p=0.021, significant |
| Central retinal vein occlusion group | 35      | 428.71| 121.90             | 20.60               |         |            |

TABLE 3: Comparison of macular edema thickness among the patients of two groups

In both groups, the ganglion cell complex thickness was 58.47 in the DME group and 66.77 in the CRVO group. Thus this showed that ganglion cell thickness was reduced to a greater extent in patients with DME.
than with CRVO (Table 4 and Figure 4).

| Group                        | Normal | Mean  | Standard Deviation | Standard Error Mean | t-Value | p-Value | Significance |
|------------------------------|--------|-------|--------------------|---------------------|---------|---------|--------------|
| Diabetic macular edema group | 35     | 58.47 | 15.24              | 2.57                | 2.02    | 0.046   | Significant  |
| Central retinal vein occlusion group | 35  | 66.77 | 19.90              | 3.36                |         |         |              |

**TABLE 4: Comparison of ganglion cell complex among the patients of two groups**

**FIGURE 4: Comparison of ganglion cell complex among the patients of two groups**

**Discussion**

This is a hospital-based cross-sectional study that analyzes the changes in the ganglion cell complex thickness in patients with DME and CRVO macular edema. In our study, a total of 70 patients (70 eyes) were included, with 35 patients each in the CRVO macular edema group and the DME group. The incidence of CRVO macular edema and DME is somewhat similar in both groups, with a mean age of 66.97 in the former and 63.94 in the latter. The incidence of CRVO macular edema and DME is more in males than females in this study. The ganglion cell complex changes in both groups showed thinning of GCC complex in both groups, slightly more in the DME group (58.47) than in the CRVO macular edema group (66.77). Macular edema in both groups was checked, and the DME group showed a mean of 370.11 and the CRVO group showed a mean of 428.71.

Neurovascular coupling is a mechanism that affects the retinal blood flow, and its effects differ in patients with diabetes mellitus and those with CRVO [9]. In diabetics, hyperglycemia activates pathways such as polyol and hexosamine, producing free radicals and advanced glycation products [2,10]. These pathways are responsible for the damage to the neural retina as they cause inflammation and ischemia, which, in turn, cause neural degeneration [11]. The most significant feature of diabetic retinopathy is neural apoptosis, and some studies have suggested the involvement of retinal ganglion and amacrine cells [2,10]. It was coupled with reactive gliosis and is responsible for the decrease in ganglion cell complex thickness in diabetic retinopathy, which can be studied effectively with OCT. Studies by van Dijk et al. showed a reduction in ganglion cell complex thickness in patients with but not without diabetic retinopathy [12,13]. Ng et al. reported ganglion cell complex loss in patients with and without diabetic retinopathy; the loss was progressive in advanced diabetic retinopathy, with a decrease in inner retinal layer thickness, as was also shown in our study [7,14].

In cases with CRVOs, damage to the photoreceptors and permanent neuronal damage due to hypoxia of the retina are causes of permanent visual loss. Fluid accumulation within the layers of the retina is responsible for Muller cell ballooning and retinal degeneration. Over a period of time, as the macular edema continues to progress, it can cause irreversible damage to neurons. It is one of the crucial causes of damage to the ganglion cell complex, leading to decreased thickness [15,16]. Secondly, toxic effects of anti-VEGF on ganglion cells could occur. Similar results were reported in this study and were seen on OCT.
However, this study also has its limitations. Firstly, the sample size for this study is small. More extensive studies with a greater sample size must confirm these results. We could not take long-term follow-up in these patients, and thus the ganglion cell complex thickness could not be analyzed over time. Also, the groups studied were not age- and gender-matched, which could further lead to a discrepancy in the results.

**Conclusions**

DME and CRVO macular edema are essential factors causing visual impairment. It is crucial to analyze this in the further management of these conditions and visual prognosis in both largely depends on the ganglion cell complex thickness which is measured on OCT. OCT provides quantitative measurement of the ganglion cell complex thickness in macular edema, which helps monitor the course of macular edema secondary to the above diseases and thereby provides assessment of the prognosis of the disease.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. Datta Meghe Institute Medical Ethical Committee issued approval DMIMS(DU)/IEC/2020-21/114. The approval has been granted by Datta Meghe Institute Medical Ethical Committee on the assumption that the proposed research work will be carried out in accordance with the ethical guidelines prescribed by Central Ethics Committee on Human Research (C.E.C.H.R.). **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Khurana AK: Comprehensive Ophthalmology. 7th Edition. Jaypee Brothers Medical Publishers, Delhi; 2019. 10.1016/j.preteyeres.2011.05.002
2. Sihotha R, Tandon R: Parsons’ Diseases of the Eye. 23rd Edition. Elsevier India, Mumbai; 2011.
3. Khurana AK, Khurana AK, Khurana B: Theory and Practice of Optics and Refraction. 4th Edition. Elsevier India, Mumbai; 2014.
4. Noma H, Funatsu H, Yamasaki M, et al.: Pathogenesis of macular edema with branch retinal vein occlusion and intracranial levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005, 140:256-61. 10.1016/j.ajo.2005.05.005
5. Kern TS, Barber AJ: Retinal ganglion cells in diabetes. J Physiol. 2008, 586:4401-8. 10.1113/jphysiol.2008.156695
6. Early Treatment Diabetic Retinopathy Study Group: 7. Grading diabetic retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie House classification: ETDRS Report Number 10. Ophthalmology. 2020, 127:S99-S119. 10.1016/j.ophtha.2020.01.050
7. Wong AC, Chan CW, Hui SP: Relationship of gender, body mass index, and axial length with central retinal thickness using optical coherence tomography. Eye (Lond). 2005, 19:292-7. 10.1038/sj.eye.6701466
8. Antonetti DA, Klein R, Gardner TW: Mechanisms of disease diabetic retinopathy. N Engl J Med. 2012, 366:1227-39.
9. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature. 2001, 414:813-20. 10.1038/351815a
10. Simó R, Hernández C: Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab. 2014, 25:23-33. 10.1016/j.tem.2013.09.005
11. Sohn, E. H, Van Dijk H.W, Jiao C: Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus. Proc. Natl Acad. Sci. USA, 113:2655-2664.
12. van Dijk HW, Verbraak FD, Kok PH, et al.: Early neurodegeneration in the retina of type 2 diabetic patients. Invest Ophthalmol Vis Sci. 2012, 55:2715-9. 10.1167/iovs.11-8997
13. van Dijk HW, Kok PH, Garvin M, et al.: Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. Invest Ophthalmol Vis Sci. 2009, 50:3404-9. 10.1167/iovs.08-3145
14. Ng DS, Chiang PP, Tan G, et al.: Retinal ganglion cell neuronal damage in diabetes and diabetic retinopathy. Clin Exp Ophthalmol. 2016, 44:243-50. 10.1111/cxo.12724
15. Ewing FM, Deary IJ, Strachan MW, Frier BM: Seeing beyond retinopathy in diabetes: electrophysiological and psychophysical abnormalities and alterations in vision. Endocr Rev. 1998, 19:462-76. 10.1210/edrv.19.4.0540

2022 Mathurkar et al. Cureus 14(10): e30609. DOI 10.7759/cureus.30609